US 12599627 B1Patent grantUnited States

Copper Nanocomposite for Cancer-Cell Screening

Official patent title

Method of treating cancer cells using copper hydroxide nitrate/calcium silicate/graphitic carbon nitride nanocomposite material

Arabic title: طريقة لعلاج الخلايا السرطانية باستخدام مادة نانو مركبة من نترات هيدروكسيد النحاس/سيليكات الكالسيوم/نتريد الكربون الغرافيتي

Invention

Problem

Cancer-cell drug resistance and nonselective cytotoxicity motivate new material screens, but candidate activity must be distinguished from toxicity to normal cells and translated beyond isolated cell lines.

Why it matters

In-vitro inhibition data can guide early preclinical research, but it cannot establish tumor selectivity, animal efficacy, safe exposure, patient benefit, or clinical treatment value.

Approach

The method grows MCF-7 or HepG-2 cancer cells in contact with a Cu2(OH)3NO3/CaSiO3@g-C3N4 nanocomposite and measures reduced viability, while separately describing microwave-assisted material preparation.

Who may benefit

Potential beneficiaries include preclinical cancer researchers, nanotoxicology laboratories, materials-chemistry groups, cell-assay developers, and early-stage oncology discovery teams.

Potential value

The disclosure combines a defined three-component porous material, microwave-assisted synthesis, physical characterization, and patent-stated viability results for two human cancer cell lines.

Background

Conventional chemotherapy can face systemic toxicity, low therapeutic index, poor delivery, and acquired resistance. Nanomaterials are investigated as carriers or active agents, but anticancer relevance requires reproducible dose-response data, mechanism, uptake, and comparison with normal cells before animal studies. The publication reports in-vitro viability effects in MCF-7 breast-carcinoma and HepG-2 hepatocellular-carcinoma lines for a copper-containing composite. The supplied evidence does not establish normal-cell selectivity, mechanism of death, genotoxicity, hemocompatibility, biodistribution, pharmacokinetics, animal efficacy, formulation, dosing, or clinical safety.

Technology overview

The main formula is Cu2(OH)3NO3/CaSiO3@g-C3N4, with each component stated at 20–40 wt. %. Cells are contacted at 3–500 μg/mL; claimed IC50 ranges are 5–15 μg/mL for HepG-2 and 20–30 μg/mL for MCF-7, while the abstract states greater than 95% inhibition in an in-vitro viability assay. Nanorods are 1–3 μm long, nanowires are 10–50 nm, pore diameter is 3–7 nm, BET area is 140–160 m2·g−1, and pore volume is 0.3–0.4 cm3·g−1.

Potential applications

Early preclinical cancer-cell viability screening.
Nanomaterial-cell interaction and uptake research.
Comparative MCF-7 and HepG-2 dose-response studies.
Copper-composite synthesis and nanotoxicology evaluation.

Evidence-supported advantages

Two human cancer cell lines are addressed in vitro.
Component proportions and cell-contact concentration are specified.
Nanorod, nanowire, surface-area, and pore ranges are defined.
A microwave-assisted synthesis route is described.

Development stage

Laboratory synthesis, material characterization, and in-vitro viability testing in MCF-7 and HepG-2 cells are described; normal-cell selectivity, mechanism, animal studies, pharmacology, and clinical validation were not established.

Commercial opportunity

This is an early in-vitro research finding, not an established cancer therapy. Development requires independent assay replication, normal-cell selectivity, copper-release and mechanism studies, genotoxicity, immunologic and blood compatibility, exposure and biodistribution, formulation, animal efficacy and toxicology, manufacturing controls, and regulatory clinical trials. Patent-stated viability effects cannot predict patient benefit or safety.

Patent classifications

WIPO IPC

A61K33/34Preparations for medical, dental or toiletry purposes
C12N5/09Microorganisms or enzymes and their compositions; propagating, preserving or maintaining microorganisms; mutation or genetic engineering; culture media

CPC

A61K33/34Preparations for medical, dental or toiletry purposes
C12N5/0693Microorganisms or enzymes and their compositions; propagating, preserving or maintaining microorganisms; mutation or genetic engineering; culture media
B82Y40/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures

Inventors

First inventorBabiker Yagoub Elhadi Abdulkhair
InventorMohamed Khairy Abdel Fattah Omran

Keywords

copper hydroxide nitrate
calcium silicate
graphitic carbon nitride
MCF-7
HepG-2
cell viability
IC50
preclinical nanomaterial

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.